{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:17Z","timestamp":1790286917201,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03061-6","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T05:01:31Z","timestamp":1716613291000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Immune checkpoint inhibitor associated epidermal necrosis, beyond SJS and TEN: a review of 98 cases"],"prefix":"10.1007","volume":"316","author":[{"given":"Eric R.","family":"Bray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel R.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey N.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George W.","family":"Elgart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Elman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea D.","family":"Maderal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,25]]},"reference":[{"key":"3061_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1203475420943260","volume":"25","author":"A Muntyanu","year":"2021","unstructured":"Muntyanu A, Netchiporouk E, Gerstein W, Gniadecki R, Litvinov IV (2021) Cutaneous Immune-related adverse events (irAEs) to Immune Checkpoint inhibitors: a Dermatology Perspective on Management. J Cutan Med Surg 25:59\u201376. https:\/\/doi.org\/10.1177\/1203475420943260","journal-title":"J Cutan Med Surg"},{"key":"3061_CR2","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1111\/ijd.14811","volume":"59","author":"NJ Maloney","year":"2020","unstructured":"Maloney NJ, Ravi V, Cheng K, Bach DQ, Worswick S (2020) Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review. Int J Dermatol 59:e183\u2013e188. https:\/\/doi.org\/10.1111\/ijd.14811","journal-title":"Int J Dermatol"},{"key":"3061_CR3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/DAD.0000000000001527","volume":"42","author":"S Robinson","year":"2020","unstructured":"Robinson S, Saleh J, Curry J, Mudaliar K (2020) Pembrolizumab-Induced Stevens-Johnson Syndrome\/Toxic epidermal necrolysis in a patient with metastatic cervical squamous cell carcinoma: a Case Report. Am J Dermatopathol 42:292\u2013296. https:\/\/doi.org\/10.1097\/DAD.0000000000001527","journal-title":"Am J Dermatopathol"},{"key":"3061_CR4","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.jaad.2020.03.029","volume":"83","author":"GE Molina","year":"2020","unstructured":"Molina GE, Yu Z, Foreman RK, Reynolds KL, Chen ST (2020) Generalized bullous mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune checkpoint inhibition: a multicenter case series. J Am Acad Dermatol 83:1475\u20131477. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.029","journal-title":"J Am Acad Dermatol"},{"key":"3061_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/1346-8138.17039","volume":"51","author":"TK Satoh","year":"2024","unstructured":"Satoh TK, Neulinger MM, Stadler P-C, Aoki R, French LE (2024) Immune checkpoint inhibitor-induced epidermal necrolysis: a narrative review evaluating demographics, clinical features, and culprit medications. J Dermatol 51:3\u201311. https:\/\/doi.org\/10.1111\/1346-8138.17039","journal-title":"J Dermatol"},{"key":"3061_CR6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","volume":"115","author":"S Bastuji-Garin","year":"2000","unstructured":"Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P (2000) SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 115:149\u2013153. https:\/\/doi.org\/10.1046\/j.1523-1747.2000.00061.x","journal-title":"J Invest Dermatol"},{"key":"3061_CR7","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ejca.2020.12.018","volume":"145","author":"C He","year":"2021","unstructured":"He C, Si X, Zhang L, Xu Y, Qu T (2021) Immune checkpoint inhibitor-related epidermal necrolysis: a rare condition with poor prognosis. Eur J Cancer 145:194\u2013196. https:\/\/doi.org\/10.1016\/j.ejca.2020.12.018","journal-title":"Eur J Cancer"},{"key":"3061_CR8","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/ddg.13876","volume":"17","author":"R Reschke","year":"2019","unstructured":"Reschke R, Mockenhaupt M, Simon J-C, Ziemer M (2019) Severe bullous skin eruptions on checkpoint inhibitor therapy - in most cases severe bullous lichenoid drug eruptions. J Dtsch Dermatol Ges 17:942\u2013948. https:\/\/doi.org\/10.1111\/ddg.13876","journal-title":"J Dtsch Dermatol Ges"},{"key":"3061_CR9","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1111\/bjd.19031","volume":"183","author":"P Basu","year":"2020","unstructured":"Basu P, Tong Y, Hinds BR, Schneider JA (2020) Nivolumab-induced toxic epidermal necrolysis with retiform purpura. Br J Dermatol 183:e32. https:\/\/doi.org\/10.1111\/bjd.19031","journal-title":"Br J Dermatol"},{"key":"3061_CR10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.36849\/JDD.6559","volume":"21","author":"O Lee","year":"2022","unstructured":"Lee O, Masood M, Nutan F (2022) Case Series of Stevens-Johnson syndrome and toxic epidermal Necrolysis with Nivolumab and Nivolumab\/ Ipilimumab Combination Therapy in Metastatic Melanoma. J Drugs Dermatol 21:529\u2013530. https:\/\/doi.org\/10.36849\/JDD.6559","journal-title":"J Drugs Dermatol"},{"key":"3061_CR11","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jaad.2022.12.048","volume":"88","author":"S Zhang","year":"2023","unstructured":"Zhang S, Tang K, Wan G, Nguyen N, Lu C, Ugwu-Dike P, Raval N, Seo J, Alexander NA, Jairath R, Phillipps J, Leung BW, Roster K, Chen W, Zubiri L, Boland G, Chen ST, Tsao H, Demehri S, LeBoeuf NR, Reynolds KL, Yu K-H, Gusev A, Kwatra SG, Semenov YR (2023) Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study. J Am Acad Dermatol 88:1024\u20131032. https:\/\/doi.org\/10.1016\/j.jaad.2022.12.048","journal-title":"J Am Acad Dermatol"},{"key":"3061_CR12","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","volume":"331","author":"JC Roujeau","year":"1994","unstructured":"Roujeau JC, Stern RS (1994) Severe adverse cutaneous reactions to drugs. N Engl J Med 331:1272\u20131285. https:\/\/doi.org\/10.1056\/NEJM199411103311906","journal-title":"N Engl J Med"},{"key":"3061_CR13","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1158\/2326-6066.CIR-19-0986","volume":"8","author":"KP Shah","year":"2020","unstructured":"Shah KP, Song H, Ye F, Moslehi JJ, Balko JM, Salem J-E, Johnson DB (2020) Demographic Factors Associated with toxicity in patients treated with anti-programmed cell Death-1 therapy. Cancer Immunol Res 8:851\u2013855. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-0986","journal-title":"Cancer Immunol Res"},{"key":"3061_CR14","doi-asserted-by":"publisher","first-page":"786046","DOI":"10.3389\/fimmu.2021.786046","volume":"12","author":"SK Wong","year":"2021","unstructured":"Wong SK, Nebhan CA, Johnson DB (2021) Impact of patient age on clinical efficacy and toxicity of checkpoint inhibitor therapy. Front Immunol 12:786046. https:\/\/doi.org\/10.3389\/fimmu.2021.786046","journal-title":"Front Immunol"},{"key":"3061_CR15","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40257-015-0158-0","volume":"16","author":"RP Dodiuk-Gad","year":"2015","unstructured":"Dodiuk-Gad RP, Chung W-H, Valeyrie-Allanore L, Shear NH (2015) Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol 16:475\u2013493. https:\/\/doi.org\/10.1007\/s40257-015-0158-0","journal-title":"Am J Clin Dermatol"},{"key":"3061_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/cup.12876","volume":"44","author":"KL Vivar","year":"2017","unstructured":"Vivar KL, Deschaine M, Messina J, Divine JM, Rabionet A, Patel N, Harrington MA, Seminario-Vidal L (2017) Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol 44:381\u2013384. https:\/\/doi.org\/10.1111\/cup.12876","journal-title":"J Cutan Pathol"},{"key":"3061_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/CJI.0000000000000112","volume":"39","author":"N Nayar","year":"2016","unstructured":"Nayar N, Briscoe K, Fernandez Penas P (2016) Toxic epidermal necrolysis-like reaction with severe Satellite Cell Necrosis Associated with Nivolumab in a patient with Ipilimumab Refractory metastatic melanoma. J Immunother 39:149\u2013152. https:\/\/doi.org\/10.1097\/CJI.0000000000000112","journal-title":"J Immunother"},{"key":"3061_CR18","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1177\/1078155219830166","volume":"25","author":"CA Dasanu","year":"2019","unstructured":"Dasanu CA (2019) Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma. J Oncol Pharm Pract 25:2052\u20132055. https:\/\/doi.org\/10.1177\/1078155219830166","journal-title":"J Oncol Pharm Pract"},{"key":"3061_CR19","doi-asserted-by":"publisher","first-page":"e15017","DOI":"10.7759\/cureus.15017","volume":"13","author":"MC Kim","year":"2021","unstructured":"Kim MC, Khan HN (2021) Nivolumab-Induced toxic epidermal necrolysis: rare but fatal complication of Immune checkpoint inhibitor therapy. Cureus 13:e15017. https:\/\/doi.org\/10.7759\/cureus.15017","journal-title":"Cureus"},{"key":"3061_CR20","unstructured":"Gallo Marin B, Oliva R, Kahn B, Borgovan T, Brooks BE, Massoud CM Pembrolizumab-induced Toxic Epidermal Necrolysis in a Patient with Metastatic Esophageal Adenocarcinoma. R I, Med J (2022) (2013) 105:34\u201336"},{"key":"3061_CR21","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2147\/OTT.S353743","volume":"15","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Cao Y, Wang X, Qian T (2022) Treatment of PD-1 inhibitor-Associated toxic epidermal necrolysis: a case report and brief review. Onco Targets Ther 15:345\u2013351. https:\/\/doi.org\/10.2147\/OTT.S353743","journal-title":"Onco Targets Ther"},{"key":"3061_CR22","doi-asserted-by":"crossref","unstructured":"Gopee NH, Gourley AM, Oliphant TJ, Hampton PJ (2020) Toxic epidermal necrolysis occurring with immune checkpoint inhibitors. Dermatol Online J 26:13030\/qt8fc428f6","DOI":"10.5070\/D3268049884"},{"key":"3061_CR23","doi-asserted-by":"publisher","first-page":"e002521","DOI":"10.1136\/jitc-2021-002521","volume":"9","author":"S Hammond","year":"2021","unstructured":"Hammond S, Olsson-Brown A, Gardner J, Thomson P, Ali S-E, Jolly C, Carr D, Ressel L, Pirmohamed M, Naisbitt D (2021) T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab. J Immunother Cancer 9:e002521. https:\/\/doi.org\/10.1136\/jitc-2021-002521","journal-title":"J Immunother Cancer"},{"key":"3061_CR24","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1111\/ajd.13704","volume":"63","author":"J Zhang","year":"2022","unstructured":"Zhang J, Zhang P, Xu Q-Y, Zhu Y-T, Chen W, Ji C (2022) Pembrolizumab associated Stevens-Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma. Australas J Dermatol 63:e71\u2013e74. https:\/\/doi.org\/10.1111\/ajd.13704","journal-title":"Australas J Dermatol"},{"key":"3061_CR25","first-page":"6","volume":"135","author":"B Rzany","year":"1996","unstructured":"Rzany B, Hering O, Mockenhaupt M, Schr\u00f6der W, Goerttler E, Ring J, Sch\u00f6pf E (1996) Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 135:6\u201311","journal-title":"Br J Dermatol"},{"key":"3061_CR26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.4065\/mcp.2009.0379","volume":"85","author":"DA Wetter","year":"2010","unstructured":"Wetter DA, Camilleri MJ (2010) Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic. Mayo Clin Proc 85:131\u2013138. https:\/\/doi.org\/10.4065\/mcp.2009.0379","journal-title":"Mayo Clin Proc"},{"key":"3061_CR27","doi-asserted-by":"publisher","first-page":"e9587","DOI":"10.7759\/cureus.9587","volume":"12","author":"D Keerty","year":"2020","unstructured":"Keerty D, Koverzhenko V, Belinc D, LaPorta K, Haynes E (2020) Immune-mediated toxic epidermal necrolysis. Cureus 12:e9587. https:\/\/doi.org\/10.7759\/cureus.9587","journal-title":"Cureus"},{"key":"3061_CR28","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.21037\/tcr-21-470","volume":"10","author":"J Cao","year":"2021","unstructured":"Cao J, Li Q, Zhi X, Yang F, Zhu W, Zhou T, Hou X, Chen D (2021) Pembrolizumab-induced autoimmune Stevens-Johnson syndrome\/toxic epidermal necrolysis with myositis and myocarditis in a patient with esophagogastric junction carcinoma: a case report. Transl Cancer Res 10:3870\u20133876. https:\/\/doi.org\/10.21037\/tcr-21-470","journal-title":"Transl Cancer Res"},{"key":"3061_CR29","doi-asserted-by":"publisher","first-page":"e2200348119","DOI":"10.1073\/pnas.2200348119","volume":"119","author":"ZI Hu","year":"2022","unstructured":"Hu ZI, Link VM, Lima-Junior DS, Delaleu J, Bouladoux N, Han S-J, Collins N, Belkaid Y (2022) Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota. Proc Natl Acad Sci U S A 119:e2200348119. https:\/\/doi.org\/10.1073\/pnas.2200348119","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3061_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16572","author":"CR Shi","year":"2023","unstructured":"Shi CR, Shaughnessy M, Sehgal K, Clark JR, Reynolds KL, Toyohara J, Chen ST (2023) Successful rechallenge with pembrolizumab after case of progressive immunotherapy-related mucocutaneous eruption (PIRME), a Stevens-Johnson syndrome-like reaction. Int J Dermatol. https:\/\/doi.org\/10.1111\/ijd.16572","journal-title":"Int J Dermatol"},{"key":"3061_CR31","doi-asserted-by":"publisher","first-page":"13030qt97g3t63v","DOI":"10.5070\/D3246040713","volume":"24","author":"KM Shah","year":"2018","unstructured":"Shah KM, Rancour EA, Al-Omari A, Rahnama-Moghadam S (2018) Striking enhancement at the site of radiation for nivolumab-induced Stevens-Johnson syndrome. Dermatol Online J 24:13030qt97g3t63v","journal-title":"Dermatol Online J"},{"key":"3061_CR32","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.lungcan.2020.09.001","volume":"148","author":"Y-T Lin","year":"2020","unstructured":"Lin Y-T, Yang JC-H, Chu C-Y (2020) Esomeprazole-induced Stevens-Johnson syndrome in a patient who underwent nivolumab therapy for advanced lung adenocarcinoma. Lung Cancer 148:177\u2013178. https:\/\/doi.org\/10.1016\/j.lungcan.2020.09.001","journal-title":"Lung Cancer"},{"key":"3061_CR33","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","volume":"22","author":"SM Goldinger","year":"2016","unstructured":"Goldinger SM, Stieger P, Meier B, Micaletto S, Contassot E, French LE, Dummer R (2016) Cytotoxic cutaneous adverse drug reactions during Anti-PD-1 therapy. Clin Cancer Res 22:4023\u20134029. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2872","journal-title":"Clin Cancer Res"},{"key":"3061_CR34","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1191\/0961203304lu2037sa","volume":"13","author":"W Ting","year":"2004","unstructured":"Ting W, Stone MS, Racila D, Scofield RH, Sontheimer RD (2004) Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): a case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions. Lupus 13:941\u2013950. https:\/\/doi.org\/10.1191\/0961203304lu2037sa","journal-title":"Lupus"},{"key":"3061_CR35","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","volume":"151","author":"M Sanlorenzo","year":"2015","unstructured":"Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, Lin K, Quaglino P, Rappersberger K, Ortiz-Urda S (2015) Pembrolizumab Cutaneous adverse events and their Association with Disease Progression. JAMA Dermatol 151:1206\u20131212. https:\/\/doi.org\/10.1001\/jamadermatol.2015.1916","journal-title":"JAMA Dermatol"},{"key":"3061_CR36","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","volume":"382","author":"R Zeiser","year":"2020","unstructured":"Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, Xu J, Wilke C, Gandhi KK, Soci\u00e9 G, REACH2 Trial Group (2020) Ruxolitinib for glucocorticoid-refractory Acute graft-versus-host disease. N Engl J Med 382:1800\u20131810. https:\/\/doi.org\/10.1056\/NEJMoa1917635","journal-title":"N Engl J Med"},{"key":"3061_CR37","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.jaad.2019.09.026","volume":"82","author":"ST Chen","year":"2020","unstructured":"Chen ST, Molina GE, Lo JA, Durbin S, Cohen JV, Reynolds KL, Kroshinsky D (2020) Dermatology consultation reduces interruption of oncologic management among hospitalized patients with immune-related adverse events: a retrospective cohort study. J Am Acad Dermatol 82:994\u2013996. https:\/\/doi.org\/10.1016\/j.jaad.2019.09.026","journal-title":"J Am Acad Dermatol"},{"key":"3061_CR38","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.jaad.2022.09.012","volume":"88","author":"TV Jacoby","year":"2023","unstructured":"Jacoby TV, Shah N, Asdourian MS, Thompson LL, Otto TS, LeBoeuf NR, Semenov Y, Dee EC, Reynolds KL, Chen ST (2023) Dermatology evaluation for cutaneous immune-related adverse events is associated with improved survival in cancer patients treated with checkpoint inhibition. J Am Acad Dermatol 88:711\u2013714. https:\/\/doi.org\/10.1016\/j.jaad.2022.09.012","journal-title":"J Am Acad Dermatol"},{"key":"3061_CR39","doi-asserted-by":"publisher","first-page":"e19202","DOI":"10.7759\/cureus.19202","volume":"13","author":"AB Ambur","year":"2021","unstructured":"Ambur AB, Mammino J, Nathoo R (2021) Recurrent Erythema Multiforme Induced by the combination of Pembrolizumab and Radiation. Cureus 13:e19202. https:\/\/doi.org\/10.7759\/cureus.19202","journal-title":"Cureus"},{"key":"3061_CR40","doi-asserted-by":"crossref","unstructured":"Sundaresan S, Nguyen KT, Nelson KC, Ivan D, Patel AB (2017) Erythema multiforme major in a patient with metastatic melanoma treated with nivolumab. Dermatol Online J 23:13030\/qt2513974h","DOI":"10.5070\/D3239036484"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03061-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03061-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03061-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T11:31:55Z","timestamp":1719401515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03061-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,25]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["3061"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03061-6","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,25]]},"assertion":[{"value":"22 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval is not required for this study in accordance with local or national guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"Eric Bray.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Reprint requests"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"233"}}